Industry context
Atrium Therapeutics Inc [RNA]
Last Updated 25 Jun 2026 @ 14:53 (Exchange is open)
Last: $12.81
-0.12%
-0.61 (↑)
GaG Algo Score™
v1.0
Short
-0.61 (↑)
Medium
-1.47 (↑)
Long
-0.97 (↑)
BUY
70.00%
return 9.28%
SELL
81.63%
return 96.45%
Line
Pivot Data
Pivot Statistics
| Metric | Average | Median | Std Dev |
|---|---|---|---|
| Gain % | 5.98% | 5.98% | 0.00% |
| Loss % | -13.42% | -13.42% | 0.37% |
| Duration | 18.0d | 15d | 7.0d |
| Total Pivots Found | 4 |
| Gain/Loss Legs | 3 (1 Gain / 2 Loss) |
| Last Pivot | Bottom @ $11.55 on 2026-06-08 |
| Change since Last Pivot | $1.28 (11.08%) |
Next Pivot Prediction Last: $12.81
| Predicted Next Type | Top |
| Predicted Price (Avg) | $12.24 |
| Predicted Price (Median) | $12.24 |
| Predicted Price Range (~68%) | $12.24 - $12.24 |
| Change to Avg Target | $-0.57 (-4.48%) |
| Predicted Date (Avg) | 2026-06-26 |
| Predicted Date Range (~68%) | 2026-06-19 - 2026-07-03 |
| Basis | Based on 1 historical gains (Avg: 5.98%, Median: 5.98%, StdDev: 0.00%) and duration (Avg: 18.0 days, StdDev: 7.0 days) |
| Note | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Atrium Therapeutics Inc edges higher, up 0.16%.
Atrium Therapeutics Inc (RNA) stock price slightly increased on Wednesday after the stock rose $0.0200 (0.16%) from the previous session on below-average volume. The stock held up slightly better than the falling NASDAQ (-0.40% down). Yesterday's trading volume was 123 375 shares, worth about $1.58M. This represents 119 025 shares less than the day before. Volume was below the 10-day average of 214 053 shares.
Atrium Therapeutics Inc signals
There is no conclusive signals given from RSI. The price is below both moving averages, and the short-term average is below the long-term average, confirming a sustained down-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (-10%), medium- (-10%), and long-term (-10%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Atrium Therapeutics Inc Support & Resistance Levels
The stock is trading above the closest support level at $12.80. approximately $0.0300 (0.23%) away. This suggests it is currently acting as a floor, consolidating near support.The sup dis das support s112.8 -
Atrium Therapeutics Inc Evaluation
- Short score: -0.61
- Medium score: -1.47
- Long score: -0.97
Ownership flow
GetAGraph InsiderPower
Transactions
250
Buy power
107.44M
Sell power
67.97M
Reliability
100/100
Buy / sell
1.58
Hist. corr.
-0.28
Latest signal
Sell 2026-05-29
Officer 182
Director 42
Executive 26
2026-01-21
Hughes Steven George Officer
Sell 2 017
2026-01-21
Hughes Steven George Officer
Sell 2 878
2026-01-21
Boyce Sarah Executive
Sell 6 394
2026-01-21
Boyce Sarah Executive
Sell 7 993
2026-01-21
Flanagan W. Michael Officer
Sell 3 976
2026-01-21
Flanagan W. Michael Officer
Sell 2 558
Relationship map
Correlation snapshot
Positioning pressure
Short interest pressure
Short interest
2.78%
Of outstanding shares
Short float
2.65%
Of tradable float
Days to cover
15.83
Short interest divided by average volume
Squeeze probability
4.50%
-2.11% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
10
EPS beats
6
EPS misses
4
Avg. surprise
1.26%
Atrium Therapeutics Inc Estimated Earnings vs Actual Earnings
Actual EPS
Estimated EPS
Beat
Q2/2023
Beat
Q3/2023
Miss
Q4/2023
Beat
Q1/2024
Beat
Q2/2024
Beat
Q3/2024
Miss
Q4/2024
Miss
Q1/2025
Waiting
Q2/2025
Waiting
Q3/2025
Atrium Therapeutics Inc Earnings History
| Date | Period | EPS estimate | Actual EPS | EPS surprise | Revenue estimate | Revenue actual | Revenue surprise |
|---|---|---|---|---|---|---|---|
| 2025-11-05 | Q3/2025 | - | - | Waiting | - | - | Waiting |
| 2025-08-08 | Q2/2025 | $-0.930 | - | Waiting | 1.61M | - | Waiting |
| 2025-05-08 | Q1/2025 | $-0.880 | $-0.900 | Miss -2.27% | 2.62M | 1.57M | Miss -40.07% |
| 2025-02-27 | Q4/2024 | $-0.760 | $-0.800 | Miss -5.26% | 2.93M | 2.97M | Beat 1.64% |
| 2024-11-07 | Q3/2024 | $-0.710 | $-0.650 | Beat 8.45% | 4.27M | 2.34M | Miss -45.29% |
| 2024-08-09 | Q2/2024 | $-0.760 | $-0.650 | Beat 14.47% | 2.64M | 2.05M | Miss -22.54% |
| 2024-05-09 | Q1/2024 | $-0.810 | $-0.790 | Beat 2.47% | 2.56M | 3.54M | Beat 38.40% |
| 2024-02-28 | Q4/2023 | $-0.540 | $-0.790 | Miss -46.30% | 12.21M | 2.19M | Miss -82.04% |
| 2023-11-08 | Q3/2023 | $-0.760 | $-0.710 | Beat 6.58% | 2.21M | 2.82M | Beat 27.51% |
| 2023-08-08 | Q2/2023 | $-0.840 | $-0.660 | Beat 21.43% | 2.14M | 2.32M | Beat 8.22% |
| 2023-05-09 | Q1/2023 | $-0.900 | $-0.740 | Beat 17.78% | 2.04M | 2.23M | Beat 9.46% |
| 2023-02-28 | Q4/2022 | $-0.840 | $-0.880 | Miss -4.76% | 2.16M | 2.77M | Beat 28.19% |
Analyst view
Analyst targets
Consensus
$25.00
Median
$25.00
Low
$25.00
High
$25.00
News flow
Latest company news
Market coverage
prnewswire.com Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Jun 23, 2026 prnewswire.com Atrium Therapeutics Reports First Quarter 2026 Financial Results May 14, 2026 prnewswire.com Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration Apr 23, 2026 prnewswire.com Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 20, 2026Company releases
Company context
Company profile
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Currency
USD
Atrium Therapeutics Inc is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid RNA therapeutics directly to the heart Their developmentstage portfolio currently includes ATR 1072 a siRNAbased therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome and ATR 1086 another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases Founded in 2025 Atrium Therapeutics is based in San Diego California
Navigation